Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors

Exclusion Criteria

• •Subjects within washout period of other anti-tumor therapies. .
• •History of prior malignancy other than the cancer under treatment in the study.
• •Major trauma or major surgery within 4 weeks before the first dose of study drug.
• •Serious nonhealing wound, ulcer, or bone fracture.
• •History of significant immune-mediated AE.
• •Central nervous system (CNS) disease involvement.
• •Any evidence of underlying severe liver dysfunction.
• •Prior organ allograft transplantations or allogeneic bone marrow, cord blood or peripheral blood stem cell transplantation.
• •Clinically significant cardiac disease with insufficient cardiac function.
• •Evidence of active uncontrolled viral, bacterial, or systemic fungal infection.
• •Known positive test result for human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS).
• •Infection of hepatitis B virus (HBV), or hepatitis C virus (HCV) (unless the disease is clinically controlled) .
• •History or risk of autoimmune disease.
• •Subjects with active severe lung infection or with a history of interstitial lung diseases, noninfectious pneumonitis, active pulmonary tuberculosis, or evidence of active pneumonitis. Clinically significant and unmanageable ascites defined as requiring constant therapeutic paracentesis.
• •Any serious underlying issue that would limit compliance with study requirements, impair the ability of the subject to understand informed consent.
• •Known hypersensitivity, allergies, or intolerance to immunoglobulins or to any excipient contained in ADG206.
• •Pregnant, lactating, or breastfeeding.